Profile data is unavailable for this security.
About the company
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
- Revenue in GBP (TTM)17.10bn
- Net income in GBP1.67bn
- Incorporated1992
- Employees61.10k
- LocationAstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 20 7304 5000
- Fax+44 20 7604 8151
- Websitehttps://www.astrazeneca.com/Home
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 4.27bn | 504.61m | 16.63bn | 14.88k | 33.07 | 3.45 | -- | 3.89 | 8.76 | 7.48 | 74.17 | 84.01 | 0.3995 | -- | -- | -- | 4.75 | 4.92 | 5.71 | 6.17 | 37.77 | 33.80 | 11.89 | 9.88 | -- | 24.06 | 0.3924 | 38.10 | 21.86 | 9.11 | -1.36 | 49.74 | 22.20 | 6.67 |
| Novo Nordisk A/S | 13.12bn | 4.53bn | 74.59bn | 42.67k | 20.88 | 15.36 | 14.94 | 5.69 | 15.92 | 15.92 | 46.11 | 21.65 | 1.05 | 1.11 | 5.21 | 2,620,712.00 | 36.25 | 38.32 | 69.04 | 70.11 | 84.25 | 84.37 | 34.54 | 33.08 | 0.7889 | -- | 0.0098 | 49.39 | 0.1209 | 6.00 | 1.31 | 8.93 | 27.77 | 12.61 |
| AstraZeneca plc | 17.10bn | 1.67bn | 77.81bn | 61.10k | 46.65 | 16.13 | 17.33 | 4.55 | 1.32 | 1.32 | 13.49 | 3.81 | 0.3563 | 1.52 | 4.17 | -- | 3.31 | 4.10 | 4.66 | 5.68 | 79.61 | 80.88 | 9.28 | 10.45 | 0.7796 | 3.16 | 0.5764 | 164.12 | -1.67 | -3.06 | -28.90 | -3.36 | -7.80 | -0.3937 |
| GlaxoSmithKline plc | 30.82bn | 3.72bn | 78.00bn | 98.46k | 20.96 | 17.89 | 13.20 | 2.53 | 0.7495 | 0.7292 | 6.21 | 0.8782 | 0.5386 | 1.76 | 4.96 | -- | 7.25 | 7.58 | 13.27 | 12.51 | 68.48 | 68.33 | 13.46 | 14.49 | 0.5091 | 11.93 | 0.8765 | 106.53 | 2.10 | 3.06 | 43.60 | -7.17 | 1.09 | 0.5076 |
| Sanofi SA | 31.22bn | 3.78bn | 82.31bn | 106.56k | 21.80 | 1.60 | 15.43 | 2.64 | 3.46 | 3.45 | 28.56 | 47.21 | 0.3378 | 0.9345 | -- | -- | 3.72 | 4.15 | 4.41 | 4.90 | 67.95 | 68.35 | 11.00 | 12.14 | 0.3985 | 26.89 | 0.2945 | 89.46 | -1.50 | 2.66 | 14.47 | 3.49 | -- | 1.86 |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2017 | 51.44m | 4.06% |
| Capital Research & Management Co. (World Investors)as of 16 Jul 2018 | 45.03m | 3.55% |
| The Vanguard Group, Inc.as of 01 Feb 2019 | 39.15m | 3.09% |
| Legal & General Investment Management Ltd.as of 01 Feb 2019 | 28.85m | 2.28% |
| Norges Bank Investment Managementas of 01 Feb 2019 | 27.10m | 2.14% |
| BlackRock Fund Advisorsas of 01 Feb 2019 | 24.01m | 1.90% |
| Dodge & Coxas of 01 Feb 2019 | 18.38m | 1.45% |
| Fidelity Management & Research Co.as of 01 Feb 2019 | 17.76m | 1.40% |
| BlackRock Advisors (UK) Ltd.as of 01 Feb 2019 | 14.05m | 1.11% |
| Franklin Advisers, Inc.as of 01 Feb 2019 | 13.56m | 1.07% |
